These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11518072)

  • 21. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines.
    Hostanska K; Reichling J; Bommer S; Weber M; Saller R
    Eur J Pharm Biopharm; 2003 Jul; 56(1):121-32. PubMed ID: 12837490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology.
    Agrosi M; Mischiatti S; Harrasser PC; Savio D
    Phytomedicine; 2000 Dec; 7(6):455-62. PubMed ID: 11194173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current St John's wort research from mode of action to clinical efficacy.
    Müller WE
    Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
    Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilavecz M
    J Am Pharm Assoc (Wash); 2001; 41(4):560-6. PubMed ID: 11486982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
    Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA
    Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. St. John's wort.
    Lawvere S; Mahoney MC
    Am Fam Physician; 2005 Dec; 72(11):2249-54. PubMed ID: 16342849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
    Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
    J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of hepatocellular toxicity associated with the components of St. John's Wort extract hypericin and hyperforin in HepG2 and HepaRG cells.
    Abegg VF; Panajatovic MV; Mancuso RV; Allard JA; Duthaler U; Odermatt A; Krähenbühl S; Bouitbir J
    Toxicol Lett; 2024 Mar; 393():1-13. PubMed ID: 38219807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
    Ng QX; Venkatanarayanan N; Ho CY
    J Affect Disord; 2017 Mar; 210():211-221. PubMed ID: 28064110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain.
    Franklin M; Reed A; Murck H
    Eur Neuropsychopharmacol; 2004 Jan; 14(1):7-10. PubMed ID: 14659982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants.
    Klier CM; Schmid-Siegel B; Schäfer MR; Lenz G; Saria A; Lee A; Zernig G
    J Clin Psychiatry; 2006 Feb; 67(2):305-9. PubMed ID: 16566628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperforin as a possible antidepressant component of hypericum extracts.
    Chatterjee SS; Bhattacharya SK; Wonnemann M; Singer A; Müller WE
    Life Sci; 1998; 63(6):499-510. PubMed ID: 9718074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of St John's wort in depression : what is known?
    Butterweck V
    CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An in vitro and hydroponic growing system for hypericin, pseudohypericin, and hyperforin production of St. John's wort (Hypericum perforatum CV new stem).
    Murch SJ; Rupasinghe HP; Saxena PK
    Planta Med; 2002 Dec; 68(12):1108-12. PubMed ID: 12494339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining hyperforin and hypericin content in eight brands of St. John's wort.
    de los Reyes GC; Koda RT
    Am J Health Syst Pharm; 2002 Mar; 59(6):545-7. PubMed ID: 11908248
    [No Abstract]   [Full Text] [Related]  

  • 36. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.
    Schempp CM; Winghofer B; Lüdtke R; Simon-Haarhaus B; Schöpf E; Simon JC
    Br J Dermatol; 2000 May; 142(5):979-84. PubMed ID: 10809859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
    Wurglics M; Schubert-Zsilavecz M
    Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line.
    Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P
    Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. St John's wort, a herbal antidepressant, activates the steroid X receptor.
    Wentworth JM; Agostini M; Love J; Schwabe JW; Chatterjee VK
    J Endocrinol; 2000 Sep; 166(3):R11-6. PubMed ID: 10974665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonist effect of pseudohypericin at CRF1 receptors.
    Simmen U; Bobirnac I; Ullmer C; Lübbert H; Berger Büter K; Schaffner W; Schoeffter P
    Eur J Pharmacol; 2003 Jan; 458(3):251-6. PubMed ID: 12504780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.